Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill codifies and clarifies value-based purchasing arrangements (VBPs) under Medicaid by amending the Medicaid drug rebate and pricing statutes.
It permits manufacturers to report multiple best-price points for a drug when offered to all States, adjusts how average manufacturer price (AMP) and Medicare average sales price (ASP) treat outcome-triggered refunds or installment payments, and creates an antikickback exception for manufacturer remuneration to States under VBPs.
The bill requires HHS and the HHS Inspector General to issue rulemaking and guidance within 180 days, directs guidance for inpatient drug VBPs and interstate cooperation, and mandates a GAO study with a report by June 30, 2029.
Technically focused and potentially bipartisan but touches contentious drug‑pricing and fraud‑and‑abuse topics; likely needs inclusion in larger package.
Relative to its intended legislative type, this bill clearly and directly amends multiple statutory provisions to enable and govern value‑based purchasing arrangements in Medicaid (and related Medicare adjustments and an antikickback carve‑out), provides definitional and calculation rules, sets rulemaking and guidance deadlines, and mandates a GAO study.
Progressive fears rebate and 340B erosion; conservatives prioritize market flexibility.
Progressive fears rebate and 340B erosion; conservatives prioritize market flexibility.
Generally supportive of value-based, patient-outcome incentives, but cautious about weakening Medicaid rebate protections and 340B program integrity.
Concerned that multiple best-price points and AMP/ASP exclusions could reduce net rebates and shift costs to states or patients without strong transparency and guardrails.
Views the bill as pragmatic to expand VBPs and remove legal barriers, with potential to lower costs and improve outcomes.
Worries about administrative complexity, budget impacts, and unintended rebate or program interactions without clear rulemaking and fiscal estimates.
Likely favorable: increases market flexibility and reduces legal barriers to innovative payment models.
Sees antikickback safe harbor and AMP/ASP clarifications as helpful to expand VBPs and encourage manufacturer participation in outcome-based contracts.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically focused and potentially bipartisan but touches contentious drug‑pricing and fraud‑and‑abuse topics; likely needs inclusion in larger package.
The bill has not accumulated any surfaced votes yet.
Progressive fears rebate and 340B erosion; conservatives prioritize market flexibility.
Technically focused and potentially bipartisan but touches contentious drug‑pricing and fraud‑and‑abuse topics; likely needs inclusion in l…
Relative to its intended legislative type, this bill clearly and directly amends multiple statutory provisions to enable and govern value‑based purchasing arrangements in Medicaid (and related Medicare adjustments and a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.